Literature DB >> 2487036

Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study.

A Calin1, J Elswood, P T Klouda.   

Abstract

In response to the continuing debate as to whether seronegative rheumatoid arthritis (RA) and seropositive RA are part of the same disease spectrum or are distinct disorders, we evaluated 720 patients with definite and classic RA, of whom 53 subjects had definite persistently seronegative destructive disease. For all but 1 seronegative RA patient, a seropositive RA case control was identified and matched for age, disease duration, degree of destruction on hand radiographs, and disease-modifying drug therapy. DR typing was undertaken on these 105 patients, together with scoring of hand radiographs. The frequency of DR4 was 69% in seropositive RA patients and 60% in seronegative RA patients (P = 0.22), versus 36% in 318 healthy controls (P = 0.008 and P = 0.007 versus seropositive and seronegative RA, respectively). Patients were matched and rematched with different controls in a series of subanalyses in order to make comparisons of hand radiograph scores. We found that HLA-DR4 was associated with destructive RA in both seropositive and seronegative RA patients. In general, DR4+ patients had more severe disease by radiologic criteria than did DR4- patients. Thus, HLA-DR4 may be an additive factor to the serologic status and may be more closely related to disease severity than to disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487036     DOI: 10.1002/anr.1780321006

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Effect of disease severity on rheumatoid arthritis concordance in same sexed siblings.

Authors:  C M Deighton; D F Roberts; D J Walker
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

Review 3.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.

Authors:  K P MacDonald; Y Nishioka; P E Lipsky; R Thomas
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

5.  HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis and amyloidosis.

Authors:  S Tiitinen; K Kaarela; A Filipowicz-Sosnowska; B Maczynska-Rusiniak; K Lehtinen; M Leirisalo-Repo; L Paimela; S Koskimies
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

6.  Examination of HLA-DR4 as a severity marker for rheumatoid arthritis in Greek patients.

Authors:  K A Boki; A A Drosos; A G Tzioufas; J S Lanchbury; G S Panayi; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

Review 7.  The role of the T cell in autoimmune inflammation.

Authors:  Alla Skapenko; Jan Leipe; Peter E Lipsky; Hendrik Schulze-Koops
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

8.  Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis.

Authors:  N A Shadick; J E Heller; M E Weinblatt; N E Maher; J Cui; G Ginsburg; J Coblyn; R Anderson; D H Solomon; R Roubenoff; A Parker
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

9.  Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy.

Authors:  T Möttönen; L Paimela; M Leirisalo-Repo; H Kautiainen; J Ilonen; P Hannonen
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 10.  Prognostic factors in rheumatoid arthritis in the era of biologic agents.

Authors:  Alla Skapenko; Iryna Prots; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2009-07-28       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.